
FDA Grants Orphan Drug Status to MB-101 for Glioblastoma, Astrocytomas
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Mustang for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and astrocytomas (anaplastic astrocytoma) and glioblastoma (GBM), according to a …